

Thursday, August 16, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, Pharm.D.
Clinton Sheffield, MD
Beth Johnson, R.Ph.

Jameson Rice, Pharm.D.
Keith Tolman, MD
Elizabeth Young, Pharm.D.

Committee Members Excused:

Ellie Brownstein, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Trevor Smith, CPhT
Merelynn Berrett, RN

Robyn Seely, Pharm.D.
Chad Hope, Pharm.D

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Charissa Anne, J&J
Michele Puyear, Gilead
Scott Larson, BMS
David Lange, Supernus
Doug Wood, Viiv
Christine Jamjian, UofU
Mechelle Beci, Gilead

Adam Shprecher, Janssen
Stuart Pappas, Janssen
Gregg Gittus, Alkermes
Kelly Ponce AstraZeneca
K Johnson, UofU
Harry Rosado-Santos, MD, UofU
Dan Brooks, Gilead

Meeting conducted by: Robyn Seely

1. Welcome & Housekeeping:

- a. Bryan Larson was welcomed as the new P&T committee manager. He was recently hired as a new pharmacist at the Department of Health.
- b. P&T Chairperson election: Clinton Sheffield was nominated as P&T chairman by Beth Young, Beth Johnson seconded, all in favor.

2. Review and Approval of April and May Minutes: Keith Tolman made a motion to approve the minutes from July. Beth Young seconded the motion. All in favor.

3. Drug Utilization Review (DUR) Board update: The DUR board reviewed Hyaluronic Acid derivative agents at the last meeting. The next DUR meeting will review CFTR

agents: Orkambi (Lumacaftor and Ivacaftor) & Kalydeco (Ivacaftor)

4. **Antiretroviral, Protease Inhibitors**– Melissa Archer presented a review of the Antiretroviral, Protease Inhibitor agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
5. **Other States Report** – Bryan Larson presented information from other States, with their Preferred Drug List listings for the Antiretroviral, Protease Inhibitor agent drug class.
6. **Public Comments:**
 - a. Adam Shprecher (Janssen) – He presented information about Prezista and Prexcobix and offered to answer questions.
 - b. Sydney Fredsen (BMS) – She presented information about Reyataz and Evotaz and offered to answer questions.
 - c. Harry Rosander-Santos (UofU provider) – He requested that the committee make the medications available as preferred agents to ensure access for patients
7. **Board Discussion:**
 - a. Chad Hope said that the reason for this review is to review safety and efficacy of individual agents and how they relate to combination agents. Utah Medicaid, as stewards of public funds must look at this, especially when the cost of combination agents can be much higher than the individual agents.
 - b. Keith Tolman asked Dr. Rosander-Santos about compliance and outcomes of using the combination agents.
 - c. Dr. Rosander-Santos said that compliance and patient satisfaction improves with the few pill regimens, but there is no safety or efficacy differences between the single vs combination agents.
 - d. Beth Johnson said that because of the fragile state of patients with this disease and problems with resistance that occur with a missed dose, access to the combination agents should not be hindered.
 - e. Chad Hope pointed out that utilization data during the past few years show that providers are using the single agents, even though the category has been open with all agents available without PA or step through.
 - f. Beth Young said that because the combination agents are not being used, there would not be a need to restrict anything at this time.
 - g. Chad said that supplement rebates offered by the manufacturers can't be claimed unless a product is on the PDL. For this reason, this class is under review.
 - h. Clinton Sheffield said that the role of the P&T committee is to review if the agents are equally safe and efficacious. He said that from discussion today, there is nothing showing that the single agents are less safe or effective than the combination agents.
 - i. Chad Hope said that because of the special nature of these drugs, a motion that requires for specific single agents drugs as preferred products.
 - j. Bryan Larson made a motion saying that the agents are equally safe and effective and as a minimum include atazanavir, darunavir, lopinavir/ritonavir and ritonavir on the preferred drug list, and allow for grandfathering of existing patients of any combination agents. Keith Tolman seconded the motion. All in favor.
 - k. Dr. Rosander-Santos expressed concern that ritonavir as a single agent may be

used, which is not recommended. Chad Hope said that the DRRC could do educational outreach in cases where ritonavir is used in this manner.

8. Meeting Adjourned

9. Next meeting is scheduled for September 17, 2015. Agents used to treat Irritable Bowel Syndrome (IBS) and Bowel Cleansing/Prep Agents will be discussed.

Minutes prepared by Trevor Smith

Recording available upon request, send email to medicaidpharmacy@utah.gov